1. Introduction
Diabetic wounds are prevalent and serious complications of diabetes mellitus, often associated with delayed healing, high recurrence rates, and an increased risk of amputation if not managed appropriately. Impaired healing of diabetic wounds is closely linked to multiple factors, including peripheral arterial disease, peripheral neuropathy, compromised immune function, and inadequate tissue oxygenation. Hyperbaric Oxygen Therapy (HBOT) delivered via hyperbaric chambers is recognized as a valuable adjunctive intervention in the management of diabetic wounds, leveraging the physiological effects of hyperbaric oxygen to support the wound healing process. This guide provides an overview of HBOT's role in diabetic wound care, covering its mechanisms of action, clinical application scope, implementation procedures, safety considerations, and current clinical evidence.
2. Mechanisms of Action of HBOT in Supporting Diabetic Wound Healing
The primary therapeutic principle of HBOT involves delivering nearly 100% oxygen (at least 95%) at pressures above atmospheric pressure (typically 1.5–3.0 atmospheres absolute, ATA) . This process significantly increases the partial pressure of oxygen in blood and tissues, addressing key challenges in diabetic wound healing through multiple pathways:
2.1 Improving Tissue Oxygenation
Individuals with diabetes often experience peripheral vascular insufficiency, leading to reduced blood flow and insufficient oxygen supply to wound sites. Under hyperbaric conditions, the solubility of oxygen in plasma increases substantially (independent of hemoglobin binding), enabling oxygen to diffuse over longer distances in tissues. This helps alleviate tissue hypoxia, a condition that can hinder the proliferation of fibroblasts, endothelial cells, and keratinocytes-all essential for wound repair.
2.2 Enhancing Angiogenesis
Adequate angiogenesis (new blood vessel formation) is critical for restoring blood supply to chronic wounds. Hyperbaric oxygen may stimulate the expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors, supporting the proliferation and migration of endothelial cells. This can accelerate the formation of new capillaries, thereby improving long-term tissue perfusion and facilitating sustained wound healing.
2.3 Supporting Immune Function
Chronic diabetic wounds are frequently complicated by bacterial infections, partly due to impaired immune function that reduces leukocytes' ability to eliminate pathogens. Oxygen is a necessary substrate for neutrophils (a type of leukocyte) to destroy bacteria through the oxidative burst mechanism. HBOT may enhance the bactericidal activity of neutrophils and inhibit the growth of anaerobic bacteria (which thrive in hypoxic environments), assisting in the management of wound infections.
2.4 Promoting Collagen Synthesis
Collagen is the main structural protein of the extracellular matrix, forming the "scaffold" for wound healing. Fibroblasts require sufficient oxygen to synthesize collagen. Hyperbaric oxygen may upregulate fibroblast activity, increasing collagen production and cross-linking. This can enhance the strength and integrity of granulation tissue, supporting wound contraction and epithelialization.
3. Clinical Indications for HBOT in Diabetic Wound Care
HBOT is not a first-line treatment for all diabetic wounds but may be recommended as an adjunctive therapy for specific types of chronic non-healing diabetic wounds that meet certain criteria, based on guidelines from organizations such as the Undersea and Hyperbaric Medical Society (UHMS). These criteria typically include:
Diabetic Foot Ulcers (DFUs) with evidence of tissue hypoxia that have not shown improvement despite at least 4 weeks of optimal standard care (including wound debridement, infection control, offloading, glycemic management, and vascular optimization).
DFUs complicated by osteomyelitis (bone infection) that is unresponsive to conventional antibiotic therapy and surgical debridement.
Diabetic wounds associated with Critical Limb Ischemia (CLI), defined as an Ankle-Brachial Index (ABI) < 0.4 or toe pressure < 30 mmHg, where revascularization surgery is not feasible or has been unsuccessful.
Diabetic wounds with limited gangrene (tissue necrosis) that are at risk of progressing to major amputation.
It is important to note that HBOT must be used in conjunction with standard wound care and cannot replace core interventions such as glycemic control, offloading, infection management, and surgical debridement.
4. Clinical Implementation of HBOT for Diabetic Wounds
4.1 Pre-Treatment Evaluation
A comprehensive assessment of the patient is required before initiating HBOT to confirm eligibility and exclude contraindications. Key evaluation components include:
Wound assessment: Size, depth, degree of necrosis, infection status, and healing progress.
Vascular assessment: Evaluation of peripheral blood flow via Ankle-Brachial Index (ABI), toe pressure measurement, Doppler ultrasound, or angiography.
Systemic assessment: Glycemic control status (Hemoglobin A1c, HbA1c), renal function, pulmonary function, ophthalmic examination (to screen for proliferative diabetic retinopathy, a relative contraindication), and medical history (e.g., history of pneumothorax, ear surgery, or claustrophobia).
4.2 Treatment Protocol
Standard HBOT protocols for diabetic wounds typically include the following parameters, which may be adjusted based on individual patient needs:
Pressure: 2.0–2.4 atmospheres absolute (ATA).
Oxygen concentration: Nearly 100% (at least 95%) .
Treatment duration: 90–120 minutes per session (including compression and decompression phases).
Frequency: 5 sessions per week, with a total course of 20–40 sessions (adjusted according to wound healing progress).
During treatment, patients are placed in a hyperbaric chamber (monoplace chambers for individual use or multiplace chambers for multiple patients). Healthcare providers monitor vital signs, oxygen saturation, and patient comfort throughout the session to ensure safety. It should be noted that hyperbaric chambers are classified as Class IIb medical devices under the European Union's Medical Devices Regulation (MDR) and must meet strict safety standards .
4.3 Post-Treatment Care
After each HBOT session, the wound should be re-evaluated and appropriately dressed. Continuous adherence to standard wound care measures (such as offloading, infection control, and glycemic management) is crucial. Regular assessments of wound size, granulation tissue formation, and pain levels are performed to monitor treatment response. If no significant improvement is observed after 10–15 sessions, the treatment plan should be re-evaluated by a healthcare professional.
5. Safety Considerations and Contraindications
5.1 Absolute Contraindications
HBOT is strictly contraindicated in patients with the following conditions due to the risk of severe adverse events:
Untreated pneumothorax (increased pressure may exacerbate lung collapse).
Intracranial air embolism (hyperbaric oxygen can expand air bubbles, potentially causing neurological damage).
Oxygen toxicity seizures (history of unresolved oxygen-induced seizures).
Certain cases of congenital spherocytosis (risk of hemolysis under hyperbaric conditions).
5.2 Relative Contraindications
For patients with the following conditions, HBOT may be considered only after a careful risk-benefit assessment and implementation of appropriate interventions:
Proliferative diabetic retinopathy (risk of worsening neovascularization; ophthalmic consultation is recommended before treatment).
Chronic Obstructive Pulmonary Disease (COPD) with carbon dioxide retention (risk of oxygen-induced hypoventilation; close monitoring of blood gas levels is required).
Renal insufficiency (potential risk of oxygen-induced oxidative stress affecting renal function).
Claustrophobia (may be managed with mild sedation or the use of a multiplace chamber with a companion).
Pregnancy (especially the first trimester; use only if the potential benefit outweighs the risk to the fetus).
5.3 Adverse Events and Mitigation Strategies
Common adverse events associated with HBOT include ear barotrauma (pain or tympanic membrane rupture due to pressure changes), sinus barotrauma, and temporary myopia (caused by oxygenation of the lens). These can be mitigated by instructing patients to perform pressure equalization techniques (e.g., swallowing, yawning) during compression and adjusting the compression rate. Rare but serious adverse events (such as oxygen toxicity and air embolism) can be prevented by strict adherence to treatment protocols and continuous monitoring by qualified healthcare personnel.
6. Clinical Evidence and Treatment Outcomes
Numerous clinical studies and meta-analyses have explored the role of HBOT in improving healing rates of chronic diabetic wounds and reducing amputation risk. For example, a 2022 meta-analysis published in the Journal of Wound Care included 15 randomized controlled trials (RCTs) and found that HBOT was associated with a higher complete healing rate of diabetic foot ulcers compared to standard care alone (relative risk RR = 1.56, 95% confidence interval CI: 1.23–1.98). Additionally, some studies suggest that HBOT may help reduce major amputation rates by 30–50% in patients with non-healing wounds and critical limb ischemia.
It should be emphasized that treatment outcomes may vary among individuals. Factors such as wound duration, severity of vascular impairment, glycemic control, and patient adherence to standard care can all influence the effectiveness of HBOT. Therefore, treatment plans should be personalized based on the patient's specific clinical condition and formulated by a qualified healthcare provider.
7. Conclusion and Future Directions
As an adjunctive treatment for chronic diabetic wounds, HBOT delivered via hyperbaric chambers may support wound healing by improving tissue oxygenation, enhancing angiogenesis, supporting immune function, and promoting collagen synthesis. When used in combination with standard wound care measures, it may contribute to improved healing rates of refractory diabetic wounds and reduced amputation risk. However, strict adherence to clinical indications, comprehensive pre-treatment evaluation, and meticulous safety monitoring are essential to ensure optimal treatment safety and effectiveness.
Future research directions include optimizing HBOT protocols (e.g., adjusting pressure, duration, and frequency), exploring combination therapy approaches (e.g., HBOT combined with stem cell therapy or growth factor therapy), and developing more portable and accessible hyperbaric devices. These advancements may help expand access to HBOT for patients with diabetic wounds, particularly in resource-limited settings.
Disclaimer: This guide is for informational purposes only and does not constitute medical advice. HBOT should only be performed under the supervision of qualified healthcare professionals in accordance with applicable medical guidelines and regulations. Hyperbaric chambers are medical devices that must comply with relevant safety standards .